AstraZeneca, MSD SHARP & DOHME

Movember 2026: Mit Schnurrbart gegen das Schweigen über Männergesundheit

München/Hamburg (ots)

Warum tragen im November plötzlich so viele Männer Schnurrbart? Dahinter steckt mehr als ein Style-Comeback: Der Movember ist ein internationaler Aktionsmonat für Männergesundheit und nutzt den Schnurrbart als Gesprächsanlass. Denn über Themen wie Prostatakrebs und Vorsorge wird oft noch zu wenig gesprochen. Das wollen AstraZeneca und MSD Sharp & Dohme gemeinsam mit Betroffenen und medizinischen Experten im Rahmen ihrer Aufklärungskampagne "Nichts verpassen" ändern und Männer dazu ermutigen, sich frühzeitig mit Prostatakrebs und den Möglichkeiten der Früherkennung auseinanderzusetzen. Prostatakrebs ist die häufigste Krebserkrankung bei Männern in Deutschland.[1] Je früher Prostatakrebs erkannt wird, desto größer sind die Chancen auf eine erfolgreiche Therapie.

Prostatakrebsfrüherkennung: Nicht aufschieben, sondern informieren

Wie wichtig es sein kann, sich frühzeitig mit der eigenen Vorsorge auseinanderzusetzen, wissen Michael und Uli Roth (@roth.zwillinge) aus eigener Erfahrung. Die ehemaligen Handball-Nationalspieler erkrankten beide mit 47 Jahren an Prostatakrebs. Ihr Appell im Movember: "Geht zur Vorsorge. Es ist wichtig, frühzeitig zum Urologen oder zur Urologin zu gehen." Alle Männer ab 45 Jahren können die Vorsorgeuntersuchung einmal im Jahr wahrnehmen, sie wird von den gesetzlichen Krankenkassen übernommen.

Doch vermeintliche Mythen, Hemmschwellen oder auch Scham rund um die Prostatakrebsfrüherkennung können Männer davon abhalten, die für sie infrage kommenden Vorsorgetermine wahrzunehmen. Urologe, Autor und Medfluencer Volker Wittkamp (@docintro) räumt deshalb mit zwei verbreiteten Annahmen auf: dass die Untersuchung zwangsläufig schmerzhaft sei und dass ohne Beschwerden auch kein Prostatakrebs vorliegen könne.

"Der Movember möchte über Männergesundheit aufklären und dazu beitragen, dass Themen wie Früherkennung und Krebserkrankungen aus der Tabuzone herauskommen", betont Prof. Thorsten Schlomm (@thorstenschlomm), Direktor der Klinik für Urologie an der Charité Berlin. "Deswegen: Redet darüber und kommt ins Gespräch - und das bitte nicht nur im November, sondern das ganze Jahr über."

Auch Prof. Markus Graefen (@markusgraefen), Gründer und ärztlicher Leiter der Martini-Klinik am UKE Hamburg, regt Männer dazu an, Verantwortung für die eigene Gesundheit zu übernehmen. Dazu gehört auch, über Prostatakrebs zu sprechen - ob im Rahmen der Vorsorge oder auch, wenn man selbst betroffen ist: "Es ist ein Tabuthema, aber ich glaube, das ist althergebracht."

Informieren, vorsorgen und offen über Prostatakrebs sprechen

Ob mit Schnurrbart oder ohne: Der Movember bietet einen Anlass, über Männergesundheit und Prostatakrebs(früherkennung) ins Gespräch zu kommen. Die Movember-Videos der medizinischen Experten und Betroffenen werden im Laufe des Novembers auf ihren Social-Media-Kanälen veröffentlicht. Vorbeischauen lohnt sich! Informationen rund um die Prostatakrebsfrüherkennung und das neue Kampagnenvideo finden Interessierte auf der "Nichts verpassen"-Website.

Wer bereits mit der Diagnose Prostatakrebs konfrontiert ist oder einen Betroffenen begleitet, findet beim "Wegweiser Prostatakrebs" verständliche Informationen zu Diagnose, Behandlung und dem Umgang mit der Erkrankung sowie weitere Unterstützungsangebote für Betroffene, Angehörige und Nahestehende im Umgang mit der Erkrankung.

#Movember #nichtsverpassen #wegweiserprostatakrebs #prostatakrebs #männergesundheit

Über AstraZeneca

Die AstraZeneca GmbH ist die deutsche Tochtergesellschaft des britisch-schwedischen Pharmaunternehmens AstraZeneca PLC. AstraZeneca (LSE/STO/Nasdaq: AZN) ist ein globales, wissenschaftsorientiertes biopharmazeutisches Unternehmen, das sich auf die Erforschung, Entwicklung und Vermarktung von verschreibungspflichtigen Medikamenten in den Bereichen Onkologie, seltene Krankheiten und Biopharmazeutika, einschließlich Herz-Kreislauf, Nieren und Stoffwechsel sowie Atemwege und Immunologie, konzentriert. AstraZeneca mit Sitz in Cambridge, Großbritannien, ist in über 125 Ländern tätig. Die innovativen Medikamente des Unternehmens werden von Millionen von Patient:innen weltweit eingesetzt. Weitere Informationen auf www.astrazeneca.de.

Über MSD

Bei MSD, in den USA und Kanada bekannt als Merck & Co., Inc., Rahway, NJ, USA, eint uns ein Ziel: Wir nutzen führende wissenschaftliche Erkenntnisse, um auf der ganzen Welt Leben zu retten und mehr Lebensqualität zu ermöglichen. Bereits seit über 130 Jahren stehen wir durch die Entwicklung wichtiger neuer Medikamente und Impfstoffe für Fortschritt. Unser Anspruch ist es, als forschendes biopharmazeutisches Unternehmen global führend zu sein - und wir entwickeln innovative Gesundheitslösungen und Wirkstoffe, die die Prävention und Behandlung von Krankheiten bei Menschen und Tieren weiter verbessern. Wir fördern Vielfalt und Inklusion in unseren Teams weltweit und handeln jeden Tag verantwortungsbewusst, um allen Menschen eine sichere, nachhaltige und gesunde Zukunft zu ermöglichen. Für weitere Informationen besuchen Sie www.msd.de und folgen Sie uns auf LinkedIn, Instagram und YouTube.

Presseinformationen von MSD sind im Internet unter www.msd-presse.de abrufbar. Fachpresseinhalte sind zugangsbeschränkt.

Über die strategische Zusammenarbeit von AstraZeneca und MSD

Im Juli 2017 gaben AstraZeneca und Merck & Co, Inc. (außerhalb der USA und Kanadas als MSD bekannt) in Kenilworth, NJ, USA, ihre globale strategische Zusammenarbeit in der Onkologie bekannt.

DE-104102/10-2026

Referenz:

[1] Robert Koch-Institut, Zentrum für Krebsregisterdaten. Krebs in Deutschland für 2021 - 2023 (15. Ausgabe, 2025) Prostatakrebs (Prostatakarzinom). Verfügbar unter: https://ots.de/3Gacqn [Zuletzt abgerufen: 02.10.2026].

Pressekontakt:

Stefanie Martha Scherpf

Manager PR & Communications

AstraZeneca GmbH

Friesenweg 26

22763 Hamburg

Tel.: +49 40 80 805-78 84

E-Mail: stefaniemartha.scherpf@astrazeneca.com

Ellen Drechsler

Senior Communication Specialist

MSD Sharp & Dohme GmbH

Levelingstr. 4a

81673 München

Tel.: +49 89 4561 1428

E-Mail: ellen.drechsler@msd.de

Original-Content von: AstraZeneca, MSD SHARP & DOHME, übermittelt durch news aktuell

From a Hurricane Ian evacuation in 2022 to more than 12,000 dogs and cats flown, the nonprofit has helped shelters in more than 30 states

ANNAPOLIS, Md., Oct. 31, 2026 /PRNewswire/ -- Race for Life Rescue, a 501(c)(3) nonprofit that flies at-risk dogs and cats from overcrowded shelters and disaster zones to shelters with room and waiting adopters, completed its 200th rescue mission on Oct. 14, flying 112 animals from Louisiana to the Northeast. The milestone comes four years after the organization's first flight. Since then, it has flown more than 12,000 animals, working with shelters in more than 30 states.

Through Dec. 31, founder Jim DeFrancesco is matching every donation, so each gift to keep the plane flying does twice the good.

"An airplane is simply a machine until you give it a purpose," said Jim DeFrancesco, founder and chief pilot of Race for Life Rescue. "When the aircraft door opens at the destination and you see rescue workers waiting to receive them, you realize that the flight wasn't simply transportation. For those animals, it was a flight to a new life."

It started with one flight

On Oct. 2, 2022, Race for Life Rescue flew its first mission, carrying relief supplies from Nashville, Tennessee, to Naples, Florida, after Hurricane Ian. The plane returned with nearly 40 displaced cats bound for adoption. Since then, the team has averaged about one mission a week, with 49 missions and 3,267 animals flown so far in 2026. Every flight is planned with shelter partners and tracked on the organization's flight map.

A commuter plane, rebuilt for rescue

Race for Life Rescue at a glance:

- Aircraft: a 1999 Beechcraft 1900D, a 19-passenger commuter plane converted to carry more than 100 crated animals in a climate-controlled cabin

- Range: about 1,000 nautical miles in under five hours, a trip that can take 20 to 25 hours by road

- Registered with the U.S. Department of Agriculture as an animal carrier

- Sending shelters screen every animal before boarding, and a partner representative flies on every mission

Shelters don't pay for flights. Race for Life Rescue covers the cost with support from donors, foundations and partners, including BISSELL Pet Foundation and the ASPCA, who help connect overcrowded shelters with places that have room.

How to help

Follow every mission on Facebook, Instagram and LinkedIn, or donate to fund the next flight. Learn more at raceforliferescue.org.

About Race for Life Rescue

Race for Life Rescue is a 501(c)(3) nonprofit that provides lifesaving air transport for dogs and cats threatened by euthanasia, natural disasters or unsafe living conditions. Founded in 2021 by Jim and Pam DeFrancesco, it flies animals from overcrowded shelters and disaster areas to partner shelters where they can be adopted. Its aircraft is based in Nashville, Tennessee, and its office is in Annapolis, Maryland. Learn more at raceforliferescue.org.

SOURCE Race For Life Rescue

Share this article

SCANOLOGY Introduces AirGO Pad for On-Site 3D Scanning, Inspection and Reporting

HANGZHOU, China, Oct. 31, 2026 /PRNewswire/ -- SCANOLOGY introduces AirGO Pad, an integrated mobile measurement platform that brings 3D scanning, inspection and reporting alongside the part being measured. Combining computing, industrial 3D inspection software and touchscreen operation, AirGO Pad works with compatible SCANOLOGY wireless 3D scanners to help operators complete the inspection workflow on-site without carrying a separate laptop.

When inspecting a large component, operators need to move around the part while keeping scan data and measurement controls accessible. Finding a suitable place for a laptopâand returning to it to check results or adjust settingsâcan interrupt that process, particularly where space is limited. AirGO Pad places the inspection interface on a portable tablet, allowing operators to view data and interact with the software beside the component.

Users can connect a compatible wireless 3D scanner and view 3D data in real time, monitoring scan coverage and quality as they work. They can then align data, perform measurements and inspect results on the same device. During scanning, operators can create comparison points, features and other inspection elements as needed. Preconfigured report templates complete the workflow, enabling standardized inspection reports to be generated directly on AirGO Pad.

The platform's design supports these transitions between scanning, inspection and reporting. Its high-definition touchscreen keeps model details and measurement results within reach. Operators can use the tablet in handheld mode while moving around the part, then unfold the convertible stand to review results on a suitable surface. A neck strap provides additional support when carrying and operating the device.

"Making a measurement system mobile means considering more than how operators carry the 3D scanner. They also need access to their data and inspection tools beside the part. We developed AirGO Pad to bring these activities together, from reviewing scan data to producing the inspection report," said a product manager at SCANOLOGY.

AirGO Pad supports SCANOLOGY's third-generation handheld and wireless optical 3D scanning systems, standard CAD/3D formats and wireless PC synchronization for measurement, annotation and review.

For product details or to request a demonstration, visit AirGo Pad product page.

About SCANOLOGY

SCANOLOGY develops industrial 3D measurement solutions for manufacturing and engineering. Its products are used for 3D measurement, automated inspection, and quality control. They are trusted by more than 10,000 enterprises across over 70 countries and regions, serving industries such as aerospace, automotive, and heavy manufacturing.

SOURCE SCANOLOGY

Share this article

HK tightens oversight of building repair work

HONG KONG, Oct. 31, 2026 /PRNewswire/ -- A report from chinadailyhk.com

The Hong Kong SAR government will launch the first phase of a centralized database for the records of building maintenance projects and professionals in May or June next year, while a new public body will assist local homeowners with the oversight of repair or renovation works from January.

The special administrative region authorities also aim to amend several ordinances to enhance crackdowns on bid-rigging and other anti-competition conduct by April.

The moves are part of the city's reforms proposed following Thursday's release of the report of an independent committee inquiry into the Wang Fuk Court blaze on Nov 26, 2025, which killed 168 people and displaced nearly 2,000 families. The report contains the judge-led panel's analysis of the cause of the fire, the system deficiencies it identified, and its recommendations for improvement.

Speaking on a radio program on Friday, Chief Secretary for Administration Eric Chan Kwok-ki said he was confident that the implementation of most of the measures proposed could begin within months.

Chan, who leads a steering committee tasked with reviewing the independent inquiry's recommendations and overseeing implementation of the proposed reforms, said the committee will hold its first meeting in November to examine in detail how to implement the proposed measures.

Chan said some measures were already being taken forward or put into effect, including amendments to six ordinances that the government is set to table in the Legislative Council by the end of this year.

But he said that the proposed centralized data system could take several months to build, as it will involve converting existing data from the data banks of various departments and developing the platform.

Chan said he believes this system will be helpful for reviewing contractors' work.

Separately, at two media briefings on Friday, officials explained how the government will support local homeowners under the new Building Maintenance Support and Services Council and criminalize bid-rigging.

Secretary for Development Bernadette Linn Hon-ho said that the council â which is set to begin operations by the end of this year, with services being launched in January â will support owners and oversee project parties involved in building inspections, tender preparations, bid evaluations and construction.

Officials said that the council's free services include providing lists of trustworthy consultants and contractors, templates of tender documents and engineering contracts, as well as the cost data from past projects, enabling homeowners to conduct bidding procedures and hire consultants and contractors.

With its paid service package â which is compulsory for homeowners applying for government repair subsidies and estimated to cost a few thousand Hong Kong dollars per household â the council will act as an agent in the recruitment of building inspection consultants and will review inspection reports, while also helping homeowners during bidding, construction and more.

Secretary for Commerce and Economic Development Algernon Yau Ying-wah said the authorities are considering criminalizing four types of serious anti-competition conduct involving tenders for building maintenance and renovation projects, namely bid-rigging, price-fixing, market sharing and output restrictions.

SOURCE chinadailyhk.com

Share this article

Drive to Great | BAIC FOTON Africa Partners Conference Successfully Held, Accelerating Localization Strategy

PORT ELIZABETH, South Africa, Oct. 31, 2026 /PRNewswire/ -- On October 29, the BAIC FOTON Africa Partners Conference, themed "Drive to Great," was held at Nelson Mandela Bay Stadium in Port Elizabeth, South Africa. Nearly 700 participants attended, including Chinese and African political and business representatives, senior executives from BAIC Group and BAIC FOTON, and distributors, key accounts, industrial partners, and media from 42 African countries.

Strategic anchoring and deeper whole-value-chain cooperation

BAIC FOTON has ranked first in China's commercial vehicle sales for 21 consecutive years and first in exports for 15 consecutive years, covering more than 140 countries and regions. From January to September 2026, export sales exceeded 168,500 units, up 43.6% year on year. In Africa, its business covers 54 markets with more than 300 authorized service outlets. At the conference, Chang Rui, CEO of BAIC Group and Chairman of the Board of BAIC FOTON, and customer representatives completed delivery of 1,000 heavy trucks in Ghana and 800 heavy trucks in Zambia. Wu Zongtian, President of BAIC FOTON International, and customer representatives signed new energy product projects: 200 units in Mozambique, 100 in Ethiopia, 100 in Kenya, and a batch project in Zambia, covering green transition scenarios in mining, agriculture, and other industries. Wu Zongtian released BAIC FOTON's internationalization and Africa regional strategy report, proposing three pillars: localized product portfolio, localized business ecosystem, and localized manufacturing and operations. BAIC FOTON will deploy fuel, natural gas, battery electric, and plug-in hybrid technology routes, using South Africa to activate Southern Africa and drive coordinated breakthroughs in East Africa, North Africa, and West Africa.

Product matrix expanded and localized manufacturing advanced

Two heavy trucks, GALAXUS R5 and GALAXUS C5, were officially launched in Africa, and the TUNLAND V PHEV pickup was released for Africa, expanding supply for heavy-duty logistics and multi-purpose mobility. Relying on 16 localized factories in Africa, BAIC FOTON continued manufacturing cooperation. At the strategic signing session, Dai Hongkai, Party Secretary of BAIC FOTON International, completed six localized manufacturing cooperation signings with partners in Tanzania, Kenya, and Zimbabwe. BAIC FOTON also advanced vehicle purchase support cooperation with WesBank and an African parts center warehouse cooperation with DP World, providing full-chain support for African users.

Market promotion deepened and GALAXUS set sail in Africa

The conference held a partners award ceremony, recognizing outstanding partners in key account development, new energy promotion, aftermarket services, and distributor cooperation. Luo Yunjie, VP of BAIC FOTON International, announced the launch of the Africa leg of the FOTON GALAXUS Global Experience and presented flags to distributor representatives from Tanzania, the Democratic Republic of the Congo, Zambia, and Zimbabwe. BAIC FOTON will continue working with local partners to deepen localized manufacturing and industrial collaboration, improve regional supply and operation service systems, and jointly embark on the new journey of "Drive to Great."

SOURCE BAIC FOTON

Share this article

GAC Wins 8 Awards, Including 4 First Prizes, Showcasing Technological Innovation Strength

SUZHOU, China, Oct. 31, 2026 /PRNewswire/ -- On October 28, GAC won 8 awards at the 2026 China-SAE Science and Technology Award ceremony in Suzhou, Jiangsu. In the fields of automotive chips, electric drive, vehicle safety, intelligent driving governance and body design, four first prizes were awarded to two GAC-led projects and two GAC-participated projects, and one GAC-led project won second prize.

In chips, GAC's led project built a full-chain path from vehicle definition to scale application, working with 105 partners to apply nearly 400 chip models and over 1,000 domestic chips. The HYPTEC GT Special Edition, China's first ICV with 100% domestically designed chips, has been launched.

In electric drive, GAC pioneered mass production of amorphous alloy stators and carbon-fiber high-speed rotors, becoming the world's only company to mass-produce amorphous alloy automotive motors. Its amorphous ribbon is just 0.025 mm thick. The motor reaches 99.03% peak efficiency, 17.29 kW/kg power density (@1000V)ânearly three times the industry mainstreamâand 30,000 rpm maximum speed; system CLTC efficiency reaches 94.184%. For users, energy consumption drops 4%, and range rises 30-50 km with the same battery capacity. It has been applied to HYPTEC, AION and AISTALAND models and promoted to other automakers. The related precision manufacturing technology won the Gold Medal with Congratulations of the Jury at the 51st International Exhibition of Inventions of Geneva.

In safety, the GAC-led project with Tsinghua University won second prize. It developed China's first ASIL-D fully domestic safety controller, real-time risk quantification, active-suspension side-impact mitigation, a rear-window airbag and an "automaker-traffic police-hospital" integrated rescue model. It has been applied to 20 models with cumulative sales of 1.446 million units.

In addition, GAC's participated L2-L4 safety governance project helped establish a full-lifecycle system covering pre-admission, in-process supervision and post-event traceability. Its participated BIW project features an AI-based body design system that generates concept schemes within 5 hours, with over 95% stiffness prediction accuracy and over 30% higher design efficiency; it has been applied to the second-generation GAC GS8, GAC ES9 and GAC All-new S7.

Looking ahead, GAC will uphold innovation-driven development, advance core technology breakthroughs and commercialization, and support high-quality development of China's auto industry.

For further information about GAC, please visit: https://www.gacgroup.com/en or follow us on social.

SOURCE GAC

Share this article

The donation of the display, featuring TCL CSOT's high-brightness Field Sequential Color technology, continues TCL's long-term commitment to the African market

DAKAR, Senegal, Oct. 31, 2026 /PRNewswire/ -- TCL, a Worldwide Olympic and Paralympic Partner, donated an ultra-low-power display system powered by solar energy to Université Amadou Mahtar Mbow (UAM) in Senegal. Delivering outdoor brightness at roughly half the power consumption of comparable displays, the system will serve as an information hub on the UAM campus, which will also serve as the Youth Olympic Village during the Dakar 2026 Youth Olympic Games.

Attendees at the donation ceremony included IOC President, Kirsty Coventry; UAM President, Professor Mababa Diagne; Senegal Higher Education Minister, Boubacar Camara; TCL Charity Ambassador, Jacky Heung; and General Manager of TCL Industries' Middle East and Africa Marketing Division, Naimin Yang.

"Powered by TCL's advanced display technology, this new display system will create new possibilities for our campus facilities and support development for both students and faculty," said Professor Diagne.

Advanced Display Technology Delivers Best in Brightness and Efficiency

The donated system features a TCL CSOT 75-inch high-brightness Field Sequential Color (FSC) display capable of delivering 4,000-nit brightness at approximately 300W. By eliminating conventional color filters and generating color through the sequential switching of red, green and blue light, FSC technology enhances light utilization with transmittance over 15%.

The technology reflects TCL CSOT's continued pursuit of improved display performance and energy efficiency, bringing advanced screens into everyday settings through TCL's broader Screen Universe vision. Installed at UAM, the display will serve as an outdoor information hub, remaining bright and clear even in direct sunlight.

TCLArt and TCLYoung Champion Local Art and the Next Generation of Creators

Beyond technology, TCL also supports local culture in Dakar through its art-focused initiative, TCLArt. TCL participates in the Yeesal urban art initiative, which works with Senegalese artists and communities to create large-scale public murals. The project supports 43 artists, especially creators under 35, whose works draw inspiration from African athletes, cultural diversity, and youth aspirations. These murals will become permanent features of Dakar's urban landscape, celebrating local creativity while reflecting TCL's commitment to the next generation of creative talent through TCLYoung.

From Local Presence to Shared Growth: TCL Deepens its Footprint in Africa

Both the donation and Yeesal partnership build on a presence in Africa stretching back more than two decades. TCL first entered the African market in 2004. Today, TCL TVs and home appliances are sold in nearly 50 African countries across the continent, supported by six sales subsidiaries and three regional business units. TCL continues to strengthen its retail presence across the region, including with the opening of the first TCL brand experience store in Africa in Johannesburg, and the establishment of its own retail and distribution channel in Kenya.

Through its established business network and localized operations, TCL continues to build closer connections with African customers and consumers, combining global technological capabilities with a deeper understanding of local markets to better serve people across the region.

About TCL

Founded in 1981, TCL is dedicated to empowering smarter, healthier lifestyles through next-generation experiences.

Today, with 50 R&D centers and 47 manufacturing bases globally, TCL operates in over 160 countries and regions, reinforcing its position as a globally competitive smart technology brand. To further inspire greatness, TCL has become an official Worldwide Olympic and Paralympic Partner in the Home Audiovisual Equipment and Home Appliances category.

SOURCE TCL Technology Group Corporation

Share this article

NEW YORK, Oct. 31, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Main Street Financial Services Corp. (OTC: MSWV) related to its merger with First Community Bankshares, Inc. Under the terms of the proposed transaction, Main Street shareholders are expected to receive 0.6174 shares of First Community Bankshares, Inc. common stock for each share of Main Street common stock. Is it a fair deal for you?

Click here for more info https://monteverdelaw.com/case/main-street-financial-services-corp/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

- Do you file class actions and go to Court?

- When was the last time you recovered money for shareholders?

- What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:

Juan Monteverde, Esq.

MONTEVERDE & ASSOCIATES PC

The Empire State Building

350 Fifth Ave. Suite 4740

New York, NY 10118

United States of America

[email protected]

Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

Share this article

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully completed patient enrollment in its pivotal Phase 2/3 clinical trial, in total enrolled 255 patients. This significant milestone marks the entry of the critical stage in the clinical development of CB03-154 for ALS in China, laying a solid foundation for the upcoming analysis of topline data and potential new drug application submissions.

This pivotal clinical trial has been conducted in China, with Professor Fan Dongsheng from the 3rd Affiliated Hospital of Peking University serving as the national leading principal investigator (Leading PI), and involving a total of 15 clinical research centers in Mainland China. The study aims to evaluate the efficacy and safety of CB03-154 in patients with ALS, with the primary efficacy endpoint being the change from baseline in the ALSFRSâR score at Week 39. Previously, CB03-154 received approval from the China CDE in July 2025 to initiate Phase 2/3 clinical trials for ALS, and in October 2023 it was granted Orphan Drug Designation (ODD) by the U.S. FDA.

As a rare disease, ALS poses numerous unique challenges in drug development. Notably, based on the current clinical progress, if the Phase 2 topline results are positive in the third quarter of 2027, Zhimeng Biopharma plans to submit a marketing application to the China CDE for a conditional approval. This strategy is expected to enable ALS patients to gain access to innovative therapies sooner, reflecting the company's patientâcentered R&D philosophy in the rareâdisease space.

CB03-154 is a next-generation, selective potassiumâchannel opener of the voltageâgated KCNQ2/3, independently discovered and developed by Zhimeng Biopharma, and possesses potential best-in-class properties. By modulating neuronal excitability and restoring the balance between excitation and inhibition, this compound has demonstrated neuroprotective effects on motor neurons in preclinical studies. The completion of enrollment in this pivotal clinical trial marks the entry of a critical phase of validating the efficacy and safety of CB03-154 in patients with ALS.

In terms of clinical development, CB03-154 has been steadily advancing across multiple CNS indications. As of October 2026, in addition to the ALS indication, the drug has already entered the Phase 2 clinical trial for Focal Epilepsy in China and Australia. Furthermore, in June 2026, it received approval from the China CDE to initiate a Phase 2 trial for Major Depressive Disorder (MDD). The concurrent advancement of these three clinical studies fully underscores CB03-154's broad development potential in the field of central nervous system disorders.

Dr. Huanming Chen, the Founder and CEO of Zhimeng Biopharma, stated: "The completion of patient enrollment for the pivotal Phase 2/3 clinical trial of CB03-154 marks a strategically significant milestone for Zhimeng Biopharma in the field of ALS treatment. I would like to extend my sincere appreciation to Professor Fan Dongsheng and the investigators at all clinical research centers across China for their dedicated efforts, as well as to all ALS patients and their families who participated in the trial for their selfless commitment. Moving forward, we will spare no effort to advance clinical development and regulatory submissions, striving to bring a truly effective new treatment option to ALS patients in China and around the world as soon as possible."

About Zhimeng

Founded in 2018, Shanghai Zhimeng Biopharma, Inc, is a clinical stage biopharmaceutical company dedicated to the research and development of original smallâmolecule drugs. The company focuses on liver diseases and central nervous system disorders, with a strong pipeline targeting treatment options for refractory epilepsy, neuropathic pain, amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and other neurological conditions. In addition to its CNS portfolio, Zhimeng Biopharma has also made significant progress in the field of functional cure for chronic hepatitis B; its leading product, ZMâH1505R (capsid inhibitor), has entered pivotal Phase 3 trial in China.

Disclaimer

This press release contains forward-looking statements. While Zhimeng considers the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

For more information, please visit: www.corebiopharma.com

SOURCE Shanghai Zhimeng Biopharma Inc.

Share this article

ScienceOra Demonstrates AI-Assisted Hydrogen-Production Catalyst Design Workflow at Tencent Global Digital Ecosystem Summit

The workflow spans literature analysis, candidate design, experimental planning and industrial decision support, extending AI4S into materials research

SHENZHEN, China, Oct. 30, 2026 /PRNewswire/ -- Wenge AI demonstrated an AI-assisted hydrogen-production catalyst design workflow supported by ScienceOra at the 2026 Tencent Global Digital Ecosystem Summit. The demonstration showed how AI for Science (AI4S) can connect literature analysis, catalyst candidate design, experimental planning and industrial decision support, helping materials researchers translate scientific evidence into actionable research plans.

ScienceOra is Wenge AI's intelligent research decision platform, built on the ScienceOne Scientific Foundation Model. For specialist research tasks such as materials development, the platform brings together scientific models, professional literature, research data and tools to support information access, research-plan development and scientific decision-making.

From literature analysis to catalyst candidate design

The demonstration focused on the design of a high-entropy alloy catalyst for the alkaline hydrogen evolution reaction. To address the need for high activity and durability, ScienceOra searched professional literature and drew on published research methods and elemental properties to support the development of candidate designs. It also cross-checked optimization proposals against relevant literature, providing researchers with references that could be reviewed and verified.

Rather than simply generating material formulations, the workflow connects documentary evidence, materials knowledge and specific design objectives to support more targeted analysis of candidate solutions. Researchers remain responsible for assessing scientific validity and determining subsequent research directions.

From experimental planning to industrial decision support

For experimental planning, ScienceOra can assist in developing research protocols around candidate designs, helping researchers organize experimental variables and producing testing standard operating procedures (SOPs) and related reference information for subsequent validation.

For industrial applications, the platform can also support comparative analysis across dimensions such as the feasibility of scaled hydrogen production, performance at industrially relevant current densities, durability, raw-material availability and compatibility with mass-production synthesis processes. It can then assist in establishing decision priorities, screening criteria and process-improvement recommendations.

Candidate designs, experimental plans, process recommendations and references can be consolidated into a structured research report, helping R&D teams assess scientific evidence alongside engineering constraints. AI provides analytical and decision support, while experimental testing and scientific validation remain essential parts of materials research.

Previously disclosed collaboration reports design efficiency and activity improvements

In a previously disclosed industryâresearch collaboration on hydrogen-production catalyst design, ScienceOra supported literature analysis and research-plan development. The collaboration reported a 38% improvement in catalyst activity and reduced the design stage from several months to 30 minutes. The case illustrates the potential of domain-specific AI to connect scientific literature, research design and engineering requirements.

ScienceOra was recently made available on Tencent WorkBuddy, with an initial offering of more than 30 research expert agents and skills covering literature analysis, research hypotheses, plan design, modeling and simulation, validation analysis and research communication. The conference demonstration further illustrated how ScienceOra can be applied to specialist materials research, as AI4S moves beyond general information processing toward support for research workflows and industrial R&D decision-making.

For more information, visit https://www.scienceone.ai/portal/.

About Wenge AI

Wenge AI (1956.HK) is a provider of artificial intelligence technology and service platform products for enterprises. With self-developed large models as its core, the company helps enterprises build practical intelligent platforms and applications. Founded by a team of AI scientists from the Chinese Academy of Sciences, Wenge AI has deep technological expertise in large models, cognitive intelligence and complex-system modeling, and is committed to advancing AI from technological capabilities to enterprise-level applications.

SOURCE Wenge AI

Share this article